secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0001193125-25-046226
Event type: m_and_a
Sentiment:  positive
Materiality: 0.88
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma to acquire Chimerix for ~$935M ($8.55/sh), adding brain-tumor drug dordaviprone
--------------------------------------------------------------------------------

- All-cash tender offer at $8.55/sh; represents ~72% premium over Chimerix's March 4 close.
- Chimerix's dordaviprone (NDA under Priority Review, PDUFA Aug 18, 2025) targets H3 K27M-mutant diffuse glioma.
- If approved, dordaviprone could be first FDA-approved therapy for this rare brain tumor; eligible for Rare Pediatric Disease PRV.
- Jazz expects to fund deal from existing cash; transaction projected to close in Q2 2025.
- Chimerix board unanimously recommends shareholders tender shares; patent protection into 2037 with potential extension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525046226/0001193125-25-046226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525046226/d927269d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-046226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer